Recruiting

I-STAMP

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT06117709

Conditions

Advanced Cancer

Pain

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

I-STAMP

Study Details

Brief summary:

The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.

Conditions

Advanced Cancer

Pain

Study ID

NCT06117709

Start date

Sep 18, 2026

Status verified date

Jul, 2026

Completion date

Apr 30, 2027

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria for Participants (Activities 1a, 2a, 3a):

  • Age ≥ 21 years
  • Current or previous diagnosis of advanced cancer
  • Current or previous experience with cancer pain

Exclusion Criteria for Participants (Activities 1a, 2a, 3a):

  • Inability to understand, speak, or read English
  • Any condition that would impede the patient's ability to complete study procedures such as visual impairment or significant cognitive impairment as determined by the participant's treating provider.

Study Design

Enrollment

73 participants

Anticipated

Intervention Model

Single group

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: I-STAMP Testing

Study procedures will be conducted as follows:

Activities 1-3: Data Collection for application development

Activity 4: To be added with future amendment

Interventions

I-STAMP

A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.

Primary outcome measure

  • Usability [ Time Frame: 2 weeks ]
  • E-scale Acceptability [ Time Frame: 2 weeks ]

Central Contacts and Locations

Central contacts

Andrea Enzinger, MD

617-582-7335Andrea_Enzinger@dfci.harvard.edu

Locations

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Andrea Enzinger, MD

617-582-7335andrea_enzinger@dfci.harvard.edu

Principal Investigator:

Andrea Enzinger, MD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Oct 13, 2026

Last verified

Jul, 2026

Keywords

  • Advanced Cancer
  • Pain management
  • Opioid pain management

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-14. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-10-13. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.